cisplatin + cyclophosphamide + methotrexate + tamoxifen

A multi-drug combination of **cisplatin**, **cyclophosphamide**, **methotrexate**, and **tamoxifen**, used experimentally or in specific regimens for treating various cancers, notably breast and ovarian cancer, in advanced or high-risk settings. - **Cisplatin** is a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis in rapidly dividing cells by forming platinum–DNA adducts, inhibiting DNA synthesis and transcription. - **Cyclophosphamide** is an alkylating agent of the nitrogen mustard class, which is converted in the body to active metabolites that crosslink DNA, resulting in cell cycle arrest and apoptosis. - **Methotrexate** is an antimetabolite and antifolate drug that inhibits dihydrofolate reductase, blocking DNA synthesis and cell replication in rapidly dividing cells. - **Tamoxifen** is a selective estrogen receptor modulator (SERM) that acts as an estrogen receptor antagonist in breast tissue, blocking estrogen-driven proliferation of cancer cells. Tamoxifen is primarily indicated for estrogen receptor-positive breast cancer and can induce cell cycle arrest and apoptosis[2][8][10]. While cisplatin, cyclophosphamide, and methotrexate are all cytotoxic chemotherapeutic agents, and tamoxifen is a hormonal agent, together they may be used as a combined modality to target both hormone-sensitive and non-hormone-sensitive cancer cell populations. This combination, however, is not a standard named regimen in current oncology guidelines and may be considered investigational or historical in certain protocols.